Literature DB >> 20693846

Myeloid-derived suppressor cells in human cancer.

Srinivas Nagaraj1, Dmitry I Gabrilovich.   

Abstract

Myeloid-derived suppressor cells are one of the major factors responsible for immune suppression in cancer. They also contribute to limited efficacy of current vaccination strategies. Here, we give an overview of the myeloid-derived suppressor cells field focusing primarily on the studies in cancer patients and current and future therapeutic options targeting these cells.

Entities:  

Mesh：

Year:  2010        PMID： 20693846     DOI： 10.1097/PPO.0b013e3181eb3358

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  122 in total

1.  Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.

Authors:  Chongyang Wu; Xiangyang Wu; Xiaoni Zhang; Ye Chai; Qi Guo; Lijuan Li; Lingling Yue; Jun Bai; Zhiping Wang; Liansheng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

Authors:  Eva Sahakian; John J Powers; Jie Chen; Susan L Deng; Fengdong Cheng; Allison Distler; David M Woods; Jennifer Rock-Klotz; Andressa L Sodre; Je-In Youn; Karrune V Woan; Alejandro Villagra; Dmitry Gabrilovich; Eduardo M Sotomayor; Javier Pinilla-Ibarz
Journal:  Mol Immunol       Date:  2014-08-23       Impact factor: 4.407

3.  Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Chao-Hung Lee
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

4.  Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.

Authors:  Binglan Zhang; Xuelei Ma; Zhimian Li; Xiang Gao; Fengtian Wang; Lei Liu; Guobo Shen; Yaxiong Sang; Minmin Li; Yuli Li; Jingyi Zhao; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-06       Impact factor: 4.553

5.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Authors:  Anahit Ghochikyan; Arpine Davtyan; Armine Hovakimyan; Hayk Davtyan; Anna Poghosyan; Alexander Bagaev; Ravshan I Ataullakhanov; Edward L Nelson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2013-10-06       Impact factor: 5.150

7.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Authors:  Cristina Iclozan; Scott Antonia; Alberto Chiappori; Dung-Tsa Chen; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

8.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

Authors:  Anandi Sawant; Jessy Deshane; Joel Jules; Carnella M Lee; Brittney A Harris; Xu Feng; Selvarangan Ponnazhagan
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

9.  Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer.

Authors:  T Schneider; A Sevko; C P Heussel; L Umansky; P Beckhove; H Dienemann; S Safi; J Utikal; H Hoffmann; V Umansky
Journal:  Clin Exp Immunol       Date:  2015-04-15       Impact factor: 4.330

10.  CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Authors:  Daniel Dubinski; Johannes Wölfer; Martin Hasselblatt; Tilman Schneider-Hohendorf; Ulrich Bogdahn; Walter Stummer; Heinz Wiendl; Oliver M Grauer
Journal:  Neuro Oncol       Date:  2015-11-17       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.